Evidence map›Paper›PMID 38214358›Full record

ArticleRecent patents on anti-cancer drug discovery2024

Human Chorionic Gonadotropin Regulates the Smad Signaling Pathway by Antagonizing TGF-β in Giant Cell Tumor of Bone.

Tangbing Xu, Shenglin Xu, Guangwen Ma, Jun Chang, Chi Zhang, Ping Zhou, Chao Wang, Pengfei Xu, Junjun Yang, Yong Hu and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Recent patents on anti-cancer drug discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tangbing XuDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Shenglin XuDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Guangwen MaDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Jun ChangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Chi ZhangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Ping ZhouDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Chao WangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Pengfei XuDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Junjun YangDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Yong HuDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Yunfeng WuDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui Province, China.
Anhui Medical University · CN

Funding

Scientific Research Fund of Anhui Medical University 2020xkj045, 2021xkj059
6 · The paper itself

Abstract

backgroundGiant cell tumor of bone (GCTB) is a locally aggressive bone tumour aggravated by stromal cell proliferation and metastasis.

objectiveWe investigated the mechanism of action of human chorionic gonadotropin (HCG) in mediating GCTB proliferation and invasion.

methodsThe expression of HCG was quantified using quantitative real-time PCR. After the primary stromal cells were isolated and identified, the function of HCG in GCTB was estimated using the cell counting kit-8, flow cytometry, scratch experiment, transwell assay, Western blot, and immunofluorescence. Moreover, the mechanism of HCG was assessed through western blotting.

resultsHCG expression was decreased in clinical tissue samples from patients with GCTB. We validated that HCG repressed stromal cell proliferation, migration, invasion, autophagy, and epithelial- mesenchymal transition (EMT) and promoted cell apoptosis in GCTB. We also verified that HCG repressed the autophagy and EMT of stromal cells through the Smad signaling axis in GCTB. HCG inhibited the transduction of the Smad signaling pathway by restraining the binding of the TGF-β II receptor to ligand Activin A.

conclusionHCG restrained the Smad signaling pathway by antagonizing TGF-β signaling in GCTB. HCG may serve as a useful patent to treat GCTB.

Indexed as

Giant Cell Tumor of BoneTransforming Growth Factor betaCell Line, TumorChorionic GonadotropinHumansPatents as TopicSignal TransductionChorionic GonadotropinTransforming Growth Factor betaautophagyepithelial-mesenchymal transition (EMT)Giant cell tumor of bone (GCTB)human chorionic gonadotropin (HCG)smad signaling pathwayTGF-β.

Identifiers

PMID38214358
PMCPMC10804236
OpenAlexW4365515590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.